IRIDEX CORP Files 8-K with Exhibits
Ticker: IRIX · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1006045
| Field | Detail |
|---|---|
| Company | Iridex Corp (IRIX) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financials
Related Tickers: IRIX
TL;DR
IRIDEX CORP filed an 8-K with exhibits, no major news.
AI Summary
On March 26, 2024, IRIDEX CORP filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions detailed in the provided text. The company is incorporated in Delaware and headquartered in Mountain View, California.
Why It Matters
This filing indicates IRIDEX CORP is meeting its regulatory reporting requirements by submitting financial statements and exhibits. Investors can review these documents for updates on the company's financial health.
Risk Assessment
Risk Level: low — The filing is a routine submission of financial statements and exhibits, not indicating any immediate operational or financial risks.
Key Players & Entities
- IRIDEX CORP (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Mountain View, California (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of March 26, 2024.
What is IRIDEX CORP's principal executive office address?
IRIDEX CORP's principal executive office is located at 1212 Terra Bella Avenue, Mountain View, California 94043.
When was the earliest event reported in this filing?
The earliest event reported in this filing is dated March 26, 2024.
What is IRIDEX CORP's fiscal year end?
IRIDEX CORP's fiscal year ends on December 31.
What is the SIC code for IRIDEX CORP?
The Standard Industrial Classification (SIC) code for IRIDEX CORP is 3845, which corresponds to Electromedical & Electrotherapeutic Apparatus.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-26 16:09:11
Key Financial Figures
- $0.01 — ch Registered Common Stock, par value $0.01 per share IRIX Nasdaq Global Market
Filing Documents
- irix-20240326.htm (8-K) — 46KB
- irix-ex99_1.htm (EX-99.1) — 208KB
- img156381773_0.jpg (GRAPHIC) — 14KB
- img156381773_1.jpg (GRAPHIC) — 10KB
- 0000950170-24-036403.txt ( ) — 414KB
- irix-20240326.xsd (EX-101.SCH) — 29KB
- irix-20240326_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 26, 2024, IRIDEX Corporation issued a press release discussing its financial results for its fourth fiscal quarter and fiscal year ended December 30, 2023. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). - 2 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IRIDEX CORPORATION By: /s/David I. Bruce David I. Bruce President and Chief Executive Officer Date: March 26, 2024 - 3 -